ScoreComparison
Why is Protalix Biotherapeutics, Inc. ?
Unrated Stock - No Analysis Available
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Protalix Biotherapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.22%
EBIT Growth (5y)
27.11%
EBIT to Interest (avg)
-0.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
1.14
Tax Ratio
24.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.63%
ROCE (avg)
58.62%
ROE (avg)
6.33%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
43
Industry P/E
Price to Book Value
4.36
EV to EBIT
31.86
EV to EBITDA
26.07
EV to Capital Employed
8.13
EV to Sales
3.28
PEG Ratio
0.28
Dividend Yield
NA
ROCE (Latest)
25.53%
ROE (Latest)
10.20%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
NET PROFIT(Q)
At USD 2.35 MM has Grown at 50.12%
-4What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -10.03 MM
INTEREST(HY)
At USD 0.96 MM has Grown at 44.59%
Here's what is working for Protalix Biotherapeutics, Inc.
Net Profit
At USD 2.35 MM has Grown at 50.12%
over average net sales of the previous four periods of USD 1.57 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Protalix Biotherapeutics, Inc.
Interest
At USD 0.96 MM has Grown at 44.59%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Cash Flow
Lowest at USD -10.03 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
